Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.
Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.
复制标题
肿瘤干细胞异质性：对化疗效果癌症分类的影响。
DOI：
--
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
Schabel Fm
中科院分区：
文献类型：
--
作者：
Skipper He;Schabel Fm
在此，我们考虑了肿瘤干细胞异质性的类型，这些异质性可能解释（a）携带特定肿瘤的类似治疗个体对化疗反应的波动程度，以及（B）根据化疗效果对癌症进行分类。突变理论预测的T/R与T/O干细胞比值的波动将解释（a）。在不同的情况下，至少有三种现象可以解释（B）：生长分数的差异，T/R与T/O干细胞比率的差异，或药物保护区的差异。T/R干细胞是最好的化疗治疗反应性、难治性和非常难治性实验性肿瘤失败的主要原因。检查的数据表明，不同类型癌症的T/R与T/O干细胞比率的差异可能解释了它们被归类为反应性，难治性或非常难治性。如果这是真的，是什么导致了这种差异？最明显的可能性是：难治性癌症中耐药状态的突变率较高，或者难治性癌症中多种T/R干细胞的某种“自然选择”。
: Herein we have considered the types of tumor stem cell heterogeneity that might account for (a) fluctuating degrees of response to chemotherapy in similarly treated individuals bearing a particular neoplasm, and (b) classifications of cancers by chemotherapeutic effect. Fluctuating ratios of T/R to T/O stem cells, as predicted by the mutation theory, will account for (a). In different circumstances at least three phenomena might account for (b): growth fraction differences, differences in T/R to T/O stem cell ratios, or differences with respect to pharmacologic sanctuaries. T/R stem cells are primarily responsible for the failure of the best available chemotherapy to cure responsive, refractory, and very refractory experimental neoplasms. The data examined suggest that differences in the T/R to T/O stem cell ratios in different types of cancer may account for their being classed as responsive, refractory, or very refractory. If this be true, what might underlie such differences? The most obvious possibilities are: higher mutation rates to a drug-resistant state in refractory cancers, or some sort of "natural selection" of diverse T/R stem cells in refractory cancers.